The outcomes revealed that compared to the Control group, the expression of GRP94, p‐PERK/PERK, p‐eIF2α/eIF2α, ATF4, FBXO2, DERL, and HSP90α genes and proteins was elevated in NASH mice, while AB23A intervention led to the downregulation of these genes and proteins in a dose‐dependent manner. This evidence concerns the gene FBXO2 and metabolic dysfunction-associated steatohepatitis.